Background: Adverse reactions to nonsteroidal anti-inflammatory drugs (NSAIDs) are commonly observed, particularly among patients with chronic urticaria or asthma. The identification of a safe and reliable alternative is a frequent problem in clinical practice. Our aim was to investigate the clinical tolerability of etoricoxib, a new selective cyclooxygenase-2 inhibitor, in a group of patients with well-established NSAID hypersensitivity. Methods: We assessed 31 adults (21 women and 10 men) who reported one or more adverse reactions to NSAIDs, manifested as cutaneous, respiratory or anaphylactic symptoms. Sixteen of them reported reactions to a single NSAID (single reactors) and 15 to more than one NSAID (multiple reactors); the most frequently involved drug was acetylsalicylic acid. First, each patient underwent allergologic tests (skin and/or oral challenge tests) with culprit NSAIDs and then tolerability tests with increasing doses of etoricoxib up to 120 mg. All challenges were performed under single-blind, placebo-controlled conditions. Results: NSAID hypersensitivity was diagnosed in all 31 patients: 3 displayed positive results to pyrazolone skin tests and the other 28 to challenges with culprit NSAIDs. None reacted to either placebos or etoricoxib. Conclusions: Etoricoxib seems to be a safe alternative for patients with well-demonstrated NSAID hypersensitivity.

1.
Mastalerz L, Setkowicz M, Sanak M, Szczeklik A: Hypersensitivity to aspirin: common eicosanoid alterations in urticaria and asthma. J Allergy Clin Immunol 2004;113:771–775.
2.
Czerniawska-Mysik G, Szczeklik A: Idiosyncrasy to pyrazolone drugs. Allergy 1981;36:381–384.
3.
Kowalski ML, Woszczek G, Bienkiewicz B, Mis M: Association of pyrazolone drug hypersensitivity with HLA-DQ and DR antigens. Clin Exp Allergy 1998;28:1153–1158.
4.
Himly M, Jahn-Schmid B, Pittertschatscher K, Bohle B, Grubmayr K, Ferreira F, et al: IgE-mediated immediate-type hypersensitivity to the pyrazolone drug propyphenazone. J Allergy Clin Immunol 2003;111:882–888.
5.
Szczeklik A, Stevenson DD: Aspirin-induced asthma: advances in pathogenesis, diagnosis, and management. J Allergy Clin Immunol 2003;111:913–921.
6.
Szczeklik A, Sanak M, Nizankowska-Mogilnicka E, Kielbasa B: Aspirin intolerance and the cyclooxygenase-leukotriene pathways. Curr Opin Pulm Med 2004;10:51–56.
7.
Quaratino D, Romano A, Papa G, Di Fonso M, Giuffreda F, Purello D’Ambrosio F, Venuti A: Long-term tolerability of nimesulide and acetaminophen in nonsteroidal anti-inflammatory drug-intolerant patients. Ann Allergy Asthma Immunol 1997;79:47–50.
8.
Quaratino D, Romano A, Di Fonso M, Papa G, Perrone MR, Purello D’Ambrosio F, Venuti A: Tolerability of meloxicam in patients with histories of adverse reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2000;84:613–617.
9.
Szczeklik A, Nizankowska E, Bochenek G, Nagraba K, Mejza F, Swierczynska M: Safety of a specific COX-2 inhibitor in aspirin-induced asthma. Clin Exp Allergy 2001;31:219–225.
10.
Stevenson DD, Simon RA: Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 2001;108:47–51.
11.
Perrone MR, Artesani MC, Viola M, Gaeta F, Caringi M, Quaratino D, Romano A: Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review. Int Arch Allergy Immunol 2003;132:82–86.
12.
Viola M, Quaratino D, Gaeta F, Caringi M, Valluzzi R, Caruso C, et al: Celecoxib tolerability in patients with hypersensitivity (mainly cutaneous reactions) to nonsteroidal anti-inflammatory drugs. Int Arch Allergy Immunol 2005;137:145–150.
13.
Viola M, Quaratino D, Volpetti S, Gaeta F, Romano A: Parecoxib tolerability in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs. J Allergy Clin Immunol 2006;117:1189–1191.
14.
Sánchez-Borges M, Caballero-Fonseca F, Capriles-Hulett A: Safety of etoricoxib, a new cyclooxygenase 2 inhibitor, in patients with nonsteroidal anti-inflammatory drug-induced urticaria and angioedema. Ann Allergy Asthma Immunol 2005;95:154–158.
15.
Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greig G, Guay J, Mancini J, Ouellet M, Wong E, Xu L, Boyce S, Visco D, Girard Y, Prasit P, Zamboni R, Rodger IW, Gresser M, Ford-Hutchinson AW, Young RN, Chan CC: Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001;296:558–566.
16.
Nettis E, Colanardi MC, Ferrannini A, Vacca A, Tursi A: Short-term tolerability of etoricoxib in patients with cutaneous hypersensitivity reactions to nonsteroidal anti-inflammatory drugs. Ann Allergy Asthma Immunol 2005;95:438–442.
17.
Zembowicz A, Mastalerz L, Setkowicz M, Radziszewski W, Szczeklik A: Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs. Arch Dermatol 2003;139:1577–1582.
18.
Nizankowska E, Bestynska-Krypel A, Cmiel A, Szczeklik A: Oral and bronchial provocation tests with aspirin for diagnosis of aspirin-induced asthma. Eur Respir J 2000;15:863–869.
19.
Stevenson DD, Sánchez-Borges M, Szczeklik A: Classification of allergic and pseudoallergic reactions to drugs that inhibit cyclooxygenase enzymes. Ann Allergy Asthma Immunol 2001;87:177–180.
20.
Aberer W, Bircher A, Romano A, Blanca M, Campi P, Fernandez J, Brockow K, Pichler WJ, Demoly P; European Network for Drug Allergy (ENDA); EAACI interest group on drug hypersensitivity: Drug provocation testing in the diagnosis of drug hypersensitivity reactions: general considerations. Allergy 2003;58:854–863.
21.
Nahar IK, Muqim AT, Al-Qhouti BI, Al-Herz AA, Shehab DK, Uppal SS, Khadadah ME: The use of etoricoxib in patients with bronchial asthma associated with aspirin sensitivity. Saudi Med J 2006;27:119–120.
22.
Messaad D, Sahla H, Benahmed S, Godard P, Bousquet J, Demoly P: Drug provocation tests in patients with a history suggesting an immediate drug hypersensitivity reaction. Ann Intern Med 2004;140:1001–1006.
23.
Lammintausta K, Kortekangas-Savolainen O: Oral challenge in patients with suspected cutaneous adverse drug reactions: findings in 784 patients during a 25-year-period. Acta Derm Venereol 2005;85:491–496.
24.
Schubert B, Grosse Perdekamp MT, Pfeuffer P, Raith P, Brocker EB, Trautmann A: Nonsteroidal anti-inflammatory drug hypersensitivity: fable or reality? Eur J Dermatol 2005;15:164–167.
25.
Morais-Almeida M, Marinho S, Rosa S, Gaspar A, Rosado-Pinto JE: Multiple drug intolerance including etoricoxib. Allergy 2006;61:144–145.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.